Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma.

J Nanobiotechnology · 2021 · PMC8088584 · PMID 33933077

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

quite significantno p-value reported

Hence, to design a combined treatment with aPD-L1 and CA4 for cancer is quite significant.

also in 5,695 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.